12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers
Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 228.5% to $7.26 during Tuesday's regular session. The company's market cap stands at $95.8 million.
Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings
Following the market opening Tuesday, the Dow traded up 0.02% to 35,627.53 while the NASDAQ fell 0.58% to 15,762.28. The S&P also fell, dropping 0.14% to 4,676.49.
Alligator Bioscience, Aptevo Therapeutics Announce Poster Presentation Of ALG.APV-527 At SITC Annual Meeting 2021
Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and
Aptevo Therapeutics Presents Clinical Data On Lead Leukemia Drug Candidate APVO436 At Second Virtual Conference On Controversies In Leukemias, Euroleuk2021
Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary
Aptevo Therapeutics Highlights Publication Of A Scientific Article In Peer-Reviewed Journal, Frontiers In Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS)
Article outlines a new strategy to employ APVO436 for targeting both MDS
Aptevo Therapeutics Announces Publication Of Scientific Article In Peer-Reviewed Journal, Frontiers In Aging
Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™
Aptevo Therapeutics Reports APVO436 Monotherapy Is Active In Patients Who Have Relapsed Acute Myeloid Leukemia Or Myelodysplastic Syndrome
Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies
Data was published in the
Aptevo Therapeutics Q2 EPS $(1.75) Up From $(2.10) YoY
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(1.75) per share. This is a 16.67 percent increase over losses of $(2.10) per share from the same period last year.